HeartLight Excalibur Balloon receives CE Mark Approval

More than 33 million patients worldwide suffer from AF.1 In Europe alone, it is estimated that the number of patients will rise to 14-17 million by 20302. 

"The new HeartLight Excalibur Balloon is designed to capitalise on the existing features of our HeartLight System, which offer an accurate, consistent and controlled treatment option for AF patients whose heart arrhythmias are insufficiently controlled with medication. Excalibur will make the procedure even easier to perform," said Burke T. Barrett, Chief Operating Officer of CardioFocus.

"The timely clinical evaluation and subsequent approval of Excalibur in Europe reflects the strong performance of the technology and highlights the significant advances made with the Excalibur Balloon." In addition to a more compliant construction that enables adaptive vein conformance, the Excalibur Balloon also incorporates proprietary Dynamic Response technology.

This feature makes the balloon highly responsive to a range of user techniques and amounts of pressure applied, while optimising vein contact. The result is designed to maximise the engagement of the balloon with the pulmonary veins, while decreasing the time required to complete ablation procedures.

"We are delighted by the results we experienced during our clinical evaluation of the HeartLight Excalibur Balloon," said Prof. Petr Neužil from Na Homolce Hospital, in Prague, Czech Republic.

"We consistently noted that the Excalibur Balloon is easier and faster to use, establishes significantly more contact with the vein and can consistently obtain an impressive antral position. I believe that this next-generation balloon will receive an enthusiastic reception by my physician colleagues."

The company plans to initiate a controlled launch of the Excalibur Balloon in Europe beginning in the fourth quarter of this year.